This is an old revision of this page, as edited by 70.89.246.57 (talk) at 03:52, 28 January 2012 (→Effectiveness profile). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 03:52, 28 January 2012 by 70.89.246.57 (talk) (→Effectiveness profile)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound| Clinical data | |
|---|---|
| Routes of administration | Subcutaneous |
| Identifiers | |
IUPAC name
| |
| ChemSpider | |
| (what is this?) (verify) | |
Insulin degludec is a ultralong-acting basal insulin analogue being developed by Novo Nordisk. It is injected subcutaneously three-times a week to help control the blood sugar level of those with diabetes. It has a duration of action that lasts up to 40 hours, unlike the 18 to 26 hours provided by current marketed long-acting insulins such as insulin glargine and insulin detemir.
Effectiveness profile
Studies have shown that patients taking insulin degludec needed to take significantly smaller doses of basal insulin than those taking insulin glargine, while achieving similar blood glucose levels. Insulin degludec also has the ability to be mixed with other insulins, thereby improving glycemic control. This cannot be done using current long-acting insulins. A physician involved in the trials was quoted as saying,
"This allows the creation of a novel formulation that retains the smooth control of a long-acting basal with rapid-acting mealtime control from insulin aspart. This 2-component insulin retains the ultralow risk characteristics of degludec with simultaneous mealtime coverage."
Insulin degludec has been filed for registration in the United States. Novo Nordisk hopes to begin marketing the insulin analog in 2013.
Side effects, contraindications and interactions
 | This section is empty. You can help by adding to it. (November 2011) |
References
- "Good News for Novo's Thrice-Weekly Insulin". DiabetesInControl.com. Retrieved 2010-11-07.
- Schwartzkopff, Frances (2010-06-25). "Novo's Degludec Insulin as Effective as Lantus With Fewer Doses". Bloomberg Businessweek. Retrieved 2010-11-07.
- "Monograph - Insulin Glargine: Dosage & Administration". American Society of Health-System Pharmacists, Inc. Retrieved 2010-11-07.
- Ringstrom, Anna (2010-06-26). "Novo says degludec has potential to lower blood sugar". Reuters. Retrieved 2010-11-07.
- Lowry, Fran. "Novel Ultralong-Acting Insulin as Effective as Insulin Glargine". Medscape. Retrieved 2010-11-07.
- "R&D Pipeline". Novo Nordisk. Retrieved 2012-27-01.
{{cite web}}: Check date values in:|accessdate=(help) - Hirschler, Ben (2010-10-27). "New Novo insulin fails to knock out rival Sanofi". Reuters. Retrieved 2010-11-07.